Our study focused on the effects of the use of tildrakizumab, a humanized IgG1κ monoclonal antibody targeting the p19 subunit of IL-23, in a cohort of 53 patients affected by moderate-to-severe psoriasis. This evidence concerns the gene IL23A and psoriasis.